RT Journal Article SR Electronic T1 High-Dose 166Ho-DOTMP in Myeloablative Treatment of Multiple Myeloma: Pharmacokinetics, Biodistribution, and Absorbed Dose Estimation JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1383 OP 1390 VO 43 IS 10 A1 Joseph G. Rajendran A1 Janet F. Eary A1 William Bensinger A1 Larry D. Durack A1 Cheryl Vernon A1 Alan Fritzberg YR 2002 UL http://jnm.snmjournals.org/content/43/10/1383.abstract AB Thirty-two patients with multiple myeloma were treated with high doses of 166Ho-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene-phosphonic acid (DOTMP) and were a subset of patients enrolled in a multicenter phase I/II dose escalation myeloablative trial. 166Ho with β-emission (half-life, 26.8 h; β-particle energies, 1.85 MeV [51%] and 1.77 MeV [48%]; γ-photons, 80.6 keV [6.6%] and 1.38 MeV [0.9%]) was complexed to DOTMP, a macrocyclic tetraphosphonate. Pharmacokinetics, dosimetry, and biodistribution were studied. Methods: Patients were treated at escalating dose levels of 20, 30, and 40 Gy to the bone marrow in combination with high-dose melphalan, with or without total-body irradiation, to evaluate toxicity and efficacy. After infusion with 1,110 MBq (30 mCi) of 166Ho-DOTMP for evaluation of biodistribution and dosimetry calculation, patients received the calculated amount of radioactivity for therapy in a single administration based on estimated dose calculations. Results: Thirty-two patients participated in the study and were then treated. The average amount of administered radioactivity was 74.3 GBq (2,007 mCi) (range, 21.5–147.5 GBq [581–3,987 mCi]) of 166Ho-DOTMP. Conclusion: 166Ho-DOTMP has physical and pharmacokinetic characteristics compatible with high-dose myeloablative treatment of multiple myeloma.